KALA.US Kala Pharmaceuticals Inc

Healthcare Pharmaceuticals USA Stocks
0.1388 USD
Close of Nov 15, 2026
3.44 2,865
Market cap
USD 89.5K
P/E
-
P/B
0.30x
ROE
-70.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is KALA.US undervalued?

Graham number

The Graham number of Kala Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kala Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Kala Pharmaceuticals Inc yet.

Kala Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kala Pharmaceuticals Inc

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC…

Full company profile